Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Other financing activities (2018 - 2025)

Historic Other financing activities for Harvard Bioscience (HBIO) over the last 13 years, with Q3 2025 value amounting to $24000.0.

  • Harvard Bioscience's Other financing activities fell 7647.06% to $24000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $569000.0, marking a year-over-year decrease of 7451.86%. This contributed to the annual value of $577000.0 for FY2024, which is 7713.04% down from last year.
  • According to the latest figures from Q3 2025, Harvard Bioscience's Other financing activities is $24000.0, which was down 7647.06% from $129000.0 recorded in Q1 2025.
  • Harvard Bioscience's 5-year Other financing activities high stood at $2.1 million for Q4 2023, and its period low was $12000.0 during Q2 2024.
  • Over the past 5 years, Harvard Bioscience's median Other financing activities value was $387000.0 (recorded in 2022), while the average stood at $493823.5.
  • Per our database at Business Quant, Harvard Bioscience's Other financing activities soared by 253000.0% in 2021 and then crashed by 9593.22% in 2024.
  • Quarter analysis of 5 years shows Harvard Bioscience's Other financing activities stood at $861000.0 in 2021, then plummeted by 46.46% to $461000.0 in 2022, then skyrocketed by 349.46% to $2.1 million in 2023, then plummeted by 79.92% to $416000.0 in 2024, then tumbled by 94.23% to $24000.0 in 2025.
  • Its Other financing activities stands at $24000.0 for Q3 2025, versus $129000.0 for Q1 2025 and $416000.0 for Q4 2024.